Antonio Rimedio
Research Subjects
Research Interests
Antonio Rimedio has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Capello
Department of Translational Medicine, Centre of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
3 shared publications - Annamaria Antona
Department of Translational Medicine, Centre of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy
2 shared publications - Carmela Rinaldi
Aging Project, Department of Translational Medicine, University of Piemonte Orientale , Novara, Italy
2 shared publications - Chiara Aleni
Department of Sustainable Development and Ecological Transition, University of Piemonte Orientale, 13100 Vercelli, Italy
2 shared publications - Daniela Ferrante
Medical Statistics, Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy
2 shared publications - Eleonora Mazzucco
UPO Biobank, University of Piemonte Orientale, 28100 Novara, Italy
2 shared publications
Latest Publications
- 27 December 2023
- Published by Springer Nature
- p. 167-175
Ethic and Biobanks
- Open Access
- 29 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 911
UPO Biobank: The Challenge of Integrating Biobanking into the Academic Environment to Support Translational Research
Biobanks are driving motors of precision and personalized medicine by providing high-quality biological material/data through the standardization and harmonization of their collection, preservation, and distribution. UPO Biobank was established in 2020 as an institutional, disease, and population biobank within the University of Piemonte Orientale (UPO) for the promotion and support of high-quality, multidisciplinary studies. UPO Biobank collaborates with UPO researchers, sustaining academic translational research, and supports the Novara Cohort Study, a longitudinal cohort study involving the population in the Novara area that will collect data and biological specimens that will be available for epidemiological, public health, and biological studies on aging. UPO Biobank has been developed by implementing the quality standards for the field and the ethical and legal issues and normative about privacy protection, data collection, and sharing. As a member of the “Biobanking and Biomolecular Resources Research Infrastructure” (BBMRI) network, UPO Biobank aims to expand its activity worldwide and launch cooperation with new national and international partners and researchers. The objective of this manuscript is to report an institutional and operational experience through the description of the technical and procedural solutions and ethical and scientific implications associated with the establishment of this university research biobank.
- 29 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 911
Open AccessUPO Biobank: The Challenge of Integrating Biobanking into the Academic Environment to Support Translational Research
Biobanks are driving motors of precision and personalized medicine by providing high-quality biological material/data through the standardization and harmonization of their collection, preservation, and distribution. UPO Biobank was established in 2020 as an institutional, disease, and population biobank within the University of Piemonte Orientale (UPO) for the promotion and support of high-quality, multidisciplinary studies. UPO Biobank collaborates with UPO researchers, sustaining academic translational research, and supports the Novara Cohort Study, a longitudinal cohort study involving the population in the Novara area that will collect data and biological specimens that will be available for epidemiological, public health, and biological studies on aging. UPO Biobank has been developed by implementing the quality standards for the field and the ethical and legal issues and normative about privacy protection, data collection, and sharing. As a member of the “Biobanking and Biomolecular Resources Research Infrastructure” (BBMRI) network, UPO Biobank aims to expand its activity worldwide and launch cooperation with new national and international partners and researchers. The objective of this manuscript is to report an institutional and operational experience through the description of the technical and procedural solutions and ethical and scientific implications associated with the establishment of this university research biobank.
- Open Access
- 11 October 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (20) , 13041
Public Attitude towards Biobanking: An Italian University Survey
Biobanks have established a critical role in biomedical research by collecting, preserving, organizing, and disseminating biospecimens and related health data, contributing to precision medicine development. Participation in biobanks is influenced by several factors, such as trust in institutions and scientists, knowledge about biobanking, and the consideration of benefit sharing. Understanding public attitudes, fears, and concerns toward biobanking is fundamental to designing targeted interventions to increase trust towards biobanks. The aim of our study was to investigate the level of knowledge and perception of biobanks in students and personnel of the University of Piemonte Orientale. An online questionnaire was designed and administered via e-mail. A total of 17,758 UPO personnel and students were invited to participate in the survey, and 1521 (9.3%) subjects completed the survey. The results showed that 65.0% of the participants were aware of the term “biobank” and knew what the activity of a biobank was, and 76.3% of subjects were willing to provide biospecimens to a research biobank, whereas 67.3% of the respondents were willing to contribute, in addition to biospecimens, their health and lifestyle data. Concerns were raised about the confidentiality of the information (25.6%) and the commercial use of the samples (25.0%). In conclusion, participants were aware of the role that biobanks play in research and were eager to participate for the sake of furthering scientific research. Still, several concerns need to be addressed regarding the confidentiality of the data along with the commercial use of the samples and associated data.
- 11 October 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (20) , 13041
Open AccessPublic Attitude towards Biobanking: An Italian University Survey
Biobanks have established a critical role in biomedical research by collecting, preserving, organizing, and disseminating biospecimens and related health data, contributing to precision medicine development. Participation in biobanks is influenced by several factors, such as trust in institutions and scientists, knowledge about biobanking, and the consideration of benefit sharing. Understanding public attitudes, fears, and concerns toward biobanking is fundamental to designing targeted interventions to increase trust towards biobanks. The aim of our study was to investigate the level of knowledge and perception of biobanks in students and personnel of the University of Piemonte Orientale. An online questionnaire was designed and administered via e-mail. A total of 17,758 UPO personnel and students were invited to participate in the survey, and 1521 (9.3%) subjects completed the survey. The results showed that 65.0% of the participants were aware of the term “biobank” and knew what the activity of a biobank was, and 76.3% of subjects were willing to provide biospecimens to a research biobank, whereas 67.3% of the respondents were willing to contribute, in addition to biospecimens, their health and lifestyle data. Concerns were raised about the confidentiality of the information (25.6%) and the commercial use of the samples (25.0%). In conclusion, participants were aware of the role that biobanks play in research and were eager to participate for the sake of furthering scientific research. Still, several concerns need to be addressed regarding the confidentiality of the data along with the commercial use of the samples and associated data.
- 25 January 2018
- Published by PAGEPress Publications in Medicina e Morale
- Vol. 66 (6) , 793-809
I soggetti vulnerabili nella ricerca clinica europea: dalla Convenzione di Oviedo al Regolamento (UE) N. 536/2014 / Vulnerable subjects in European clinical research: from the Oviedo Convention to Regulation (EU) No 536/2014
Il confronto tra la Convenzione di Oviedo e il Regolamento (UE) N. 536/2014 ha consentito di strutturare lo “standard etico-giuridico” europeo relativo alle misure di protezione dei soggetti vulnerabili coinvolti nelle sperimentazioni cliniche. Tale standard è stato analizzato seguendo il filo conduttore dei tre principi fondamentali della ricerca, enunciati dal Belmont Report: rispetto per la persona, beneficialità e giustizia. Le discrepanze riscontrate al suo interno hanno fatto emergere le criticità di talune categorie di base, ad esempio la distinzione tra beneficio diretto o beneficio sul gruppo e la nozione del rischio minimo. A 20 anni di distanza dalla Convenzione di Oviedo, documento di riferimento della bioetica europea ed internazionale, viene argomentata la necessità di ripensare criticamente quella dimensione “difensiva” della vulnerabilità, che prevale nella normativa europea e occidentale. ---------- The comparison between the Oviedo Convention and the Regulation (EU) No. 536/2014 has allowed to discover and structure the European “ethical-legal standard” on the protection measures for vulnerable subjects involved in clinical trials. This standard was analyzed following the three fundamental principles of research, as outlined by the Belmont Report: respect for persons, beneficence and justice. The discrepancies found inside have highlighted the criticalities of some basic categories, such as the distinction between direct benefit or benefit on the group and the notion of minimal risk. Twenty years after the Oviedo Convention, a reference document for European and international bioethics, there is a need to rethink critically the “defensive” dimension of vulnerability, that prevails in European and Western legislation.
- 25 January 2018
- Published by PAGEPress Publications in Medicina e Morale
- Vol. 66 (6) , 793-809
I soggetti vulnerabili nella ricerca clinica europea: dalla Convenzione di Oviedo al Regolamento (UE) N. 536/2014 / Vulnerable subjects in European clinical research: from the Oviedo Convention to Regulation (EU) No 536/2014
Il confronto tra la Convenzione di Oviedo e il Regolamento (UE) N. 536/2014 ha consentito di strutturare lo “standard etico-giuridico” europeo relativo alle misure di protezione dei soggetti vulnerabili coinvolti nelle sperimentazioni cliniche. Tale standard è stato analizzato seguendo il filo conduttore dei tre principi fondamentali della ricerca, enunciati dal Belmont Report: rispetto per la persona, beneficialità e giustizia. Le discrepanze riscontrate al suo interno hanno fatto emergere le criticità di talune categorie di base, ad esempio la distinzione tra beneficio diretto o beneficio sul gruppo e la nozione del rischio minimo. A 20 anni di distanza dalla Convenzione di Oviedo, documento di riferimento della bioetica europea ed internazionale, viene argomentata la necessità di ripensare criticamente quella dimensione “difensiva” della vulnerabilità, che prevale nella normativa europea e occidentale. ---------- The comparison between the Oviedo Convention and the Regulation (EU) No. 536/2014 has allowed to discover and structure the European “ethical-legal standard” on the protection measures for vulnerable subjects involved in clinical trials. This standard was analyzed following the three fundamental principles of research, as outlined by the Belmont Report: respect for persons, beneficence and justice. The discrepancies found inside have highlighted the criticalities of some basic categories, such as the distinction between direct benefit or benefit on the group and the notion of minimal risk. Twenty years after the Oviedo Convention, a reference document for European and international bioethics, there is a need to rethink critically the “defensive” dimension of vulnerability, that prevails in European and Western legislation.